DNMT3L is part of the DNA methyltransferase family, which includes DNMT1, DNMT3A, and DNMT3B. Unlike DNMT3A and DNMT3B, which are responsible for de novo DNA methylation, DNMT3L itself lacks catalytic activity. Instead, it acts as a regulatory factor that enhances the activity of DNMT3A and DNMT3B by forming complexes with them . This interaction is essential for the establishment of DNA methylation patterns during embryonic development, genomic imprinting, and X-chromosome inactivation .
DNA methylation is a critical epigenetic modification that influences various biological processes, including:
The study of DNMT3L has significant implications in understanding epigenetic regulation and its impact on health and disease. Abnormal DNA methylation patterns are associated with various diseases, including cancer, neurological disorders, and developmental abnormalities . Research on DNMT3L and its interactions with other DNA methyltransferases can provide insights into the mechanisms underlying these conditions and potentially lead to therapeutic interventions.
In the context of recombinant protein production, human DNMT3L can be expressed and purified for use in biochemical assays and structural studies. This recombinant form allows researchers to investigate the enzyme’s properties and interactions in a controlled environment, facilitating the development of targeted therapies and diagnostic tools .